Bone marrow-derived mesenchymal stem cells microvesicles stabilize atherosclerotic plaques by inhibiting...

Area of Science:

• Cardiovascular Research
• Stem Cell Biology
• Molecular Medicine

Background:

• Atherosclerotic plaque rupture is a primary cause of thrombosis and acute ischemic coronary syndrome.
• Bone marrow-derived mesenchymal stem cells microvesicles (BMSCs-MVs) show potential in promoting angiogenesis.
• The role of BMSCs-MVs in stabilizing atherosclerotic plaques requires further investigation.

Purpose of the Study:

• To investigate the therapeutic potential of BMSCs-MVs in stabilizing atherosclerotic plaques.
• To elucidate the underlying molecular mechanisms, including the involvement of microRNA-223 (miR-223) and NLRP3 inflammasome.

Main Methods:

• Isolation and characterization of BMSCs-MVs in a mouse model of atherosclerosis.
• In vitro studies using a macrophage model with high glucose and oxidative damage.
• Detection of NLRP3, pyroptosis-related proteins, inflammatory factors, and miR-223.
• Experimental manipulation of miR-223 and NLRP3 expression.

Main Results:

• BMSCs-MVs reduced atherosclerotic plaque vulnerability and intima-media thickness in mice.
• BMSCs-MVs inhibited pyroptosis and inflammatory factor release in macrophages.
• BMSCs-MVs delivered miR-223, which directly targeted and inhibited NLRP3 expression, thereby reducing pyroptosis.

Conclusions:

• BMSCs-MVs demonstrate significant plaque-stabilizing effects in atherosclerosis.
• The therapeutic action of BMSCs-MVs is mediated by the miR-223/NLRP3 pathway, suppressing macrophage pyroptosis and inflammation.
• BMSCs-MVs represent a promising cell-free therapy for atherosclerosis management.